Despite EGFR being highly expressed in a large proportion of TNBC patients, the employment of engineered monoclonal antibodies (mABs) against EGFR is not approved for the treatment of breast cancer, while it is approved for other types of cancer such as colorectal cancer. The gene discussed is EGFR; the disease is breast carcinoma.